Longer vs Shorter Schedules of Vincristine, Irinotecan, and Temozolomide for Relapsed or Refractory Ewing Sarcoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Longer versus shorter schedules of vincristine, irinotecan and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial
Clin. Cancer Res 2023 Jan 09;[EPub Ahead of Print], J Xu, L Xie, X Sun, K Liu, X Liang, Z Cai, X Tang, W GuoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.